Cargando…
Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions
Prognosis of diffuse large B-cell lymphoma (DLBCL) has considerably improved during the last decade, mainly due to the addition of rituximab to chemotherapy. However, a significant proportion of patients still experience primary refractory disease or short-term relapses, conferring poor survival. Th...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3621721/ https://www.ncbi.nlm.nih.gov/pubmed/23579927 http://dx.doi.org/10.2147/OTT.S42574 |